| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10011452 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
| TVIS10011453 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
| TVIS10021160 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SERPINC1 |
|---|---|
| DrugBank ID | DB08813 |
| Drug Name | Nadroparin |
| Target ID | BE0000280 |
| UniProt ID | P01008 |
| Regulation Type | potentiator |
| PubMed IDs | 9108990; 8707165 |
| Citations | Davis R, Faulds D: Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997 Apr;10(4):299-322.@@Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
